China Inspection and Testing Society (CITS) Launches First-Ever Home Medical Testing Delivery Service Standard
The China Inspection and Testing Society (CITS) has announced the release of the T/CITS 172—2024 "Specifications for Home Medical Testing Delivery Services," marking the first group standard in China dedicated to home medical testing delivery services. This significant milestone signifies a new phase of standardized development for this burgeoning service model, which has been gaining traction in the healthcare industry.
About the Standard:The T/CITS 172—2024 standard delineates the service model, basic requirements, service processes, management, and evaluation and improvement measures for home medical testing delivery services. It is designed to be applicable to third-party platforms that integrate sampling product suppliers, medical testing laboratories, and logistics service providers.
Significance and Scope:This standardization effort addresses the growing demand for convenient and timely medical testing services outside of traditional healthcare settings. By specifying the service model and requirements, the T/CITS 172—2024 standard aims to enhance the convenience and timeliness of medical services while providing a solid foundation for the healthy development of the industry.
Benefits and Implications:The establishment of this standard is a critical step in responding to market demand and protecting consumer rights, and promoting the standardized development of the home medical testing delivery service industry. It is expected that with the standardization of these services, there will be an increase in the adoption of home testing models for infectious diseases, chronic disease management, and other medical services, potentially bypassing traditional hospital settings.
Xiamen Wiz Biotech Co., Ltd is a point of care test manufacturer in China, devoted itself to become the expert of POCT solution provider. Besides test reagents, Wizbiotech also develops immunoassay analyzer to meet the needs of customers. Wizbiotech has obtained two registrations for home use products in China, calprotectin test and fecal occult blood test, which aids in improving the rate of colonrectal cancer screening participation.
